What Myriad Genetics Doubters Saw Before The Drop

Myriad Genetics reported sharply lower revenue in Q2 2026 but a much smaller loss, a mix that might sound like progress for the business. For Myriad Genetics shareholders, the loss over the past year was 46.2%, including dividends. If you had been weighing an investment back in October 2025, with both bullish and cautious analyst views already on record, which early signals would you have focused on before this drop forced the question?

On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.

Myriad Genetics has already moved. Pinpoint other ways to investigate the theme among 34 healthcare AI stocks.

The Two Myriad Genetics Stories Investors Were Weighing

The shares cost US$8.1 at the start of the period, and anyone looking at Myriad Genetics then was choosing between two quite different stories built on the same data.

The bullish Narrative set a Fair Value of US$14.33 and leaned on the idea that genomics plus AI could reshape precision oncology, with assumptions such as 6.0% revenue growth and profit margins eventually reaching 13.8%.

The more cautious Narrative put Fair Value at US$7.31 and stressed risks such as payer pushback, including UnitedHealthcare's GeneSight decision, as well as the higher interest burden from the new OrbiMed loan.

What The Results Changed For Myriad Genetics

The clearest signal was Myriad Genetics cutting full year revenue guidance to a midpoint of US$780 million after Q2 2026 revenue came in at US$190.7 million, below Q2 2025's US$213.1 million, which challenged the more optimistic growth story. Net loss excluding extra items narrowed from US$330.5 million to US$43.2 million and net margin improved to a 22.7% loss, so profitability progress remained unproven but did not support the most cautious fears. Overall, the evidence cut both ways.

The lesson is simple. When a story leans on multi year expansion, treat revenue guidance, not just reported sales, as the key assumption to test each quarter.

What You Would Be Paying For In Myriad Genetics Today

With Myriad Genetics now trading at US$4.35 after a 46.2% loss over the past year, the selected Narrative still places its Fair Value above that level, based on its own assumptions rather than any hard verdict.

The bullish case leans heavily on cancer testing, arguing that AI driven tumor profiling, reimbursement gains, and a possible prenatal exit could reshape the earnings profile. For the fall to look like an opening rather than a warning, a buyer today would need confidence that oncology execution and payer support genuinely remain on that trajectory.

"Analysts broadly agree that partnerships like the PATHOMIQ collaboration could accelerate oncology revenue, but this likely understates the transformative impact. Being the only provider combining AI, biomarker, germline, and tumor profiling positions Myriad to capture disproportionate share as precision cancer care standards shift, unlocking outsized multi-year revenue growth and pricing power."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Following Myriad Genetics One Step Away

Thinking about Myriad Genetics, you are really asking how biology and data change treatment.

One step away, another business tackles the same question from a different angle. It builds medicines that reshape how metabolic disease and obesity are treated.

Where Myriad focuses on testing, this other player concentrates on powerful injectable therapies and an upcoming pill version. That mix aims to make treatment both more effective and easier to start.

The interesting part is what happens if appetite, blood sugar, heart health and even joint pain are all addressed together. That is a different kind of optionality to weigh alongside Myriad.

One Narrative has already put a figure on it. → Uncover the company trading 15% below one Narrative's Fair Value

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com